Altan Turkoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Altan Turkoglu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- John C. Byrd
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
29 shared publications - Kerry A. Rogers
Ohio State University, Columbus, Ohio, United States
29 shared publications - Alexander He
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - Annika Chura
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - Bradley W. Blaser
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
18 shared publications - Britten K. Gordon
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S6. Supporting data for Figure 3. Expression of selected T cell phenotypic markers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S6. Supporting data for Figure 3. Expression of selected T cell phenotypic markers.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S7: Genes expressed in CD16+ monocytes
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S7: Genes expressed in CD16+ monocytes
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S4. Supporting data for Figure 1. Expression of genes related to BCR signaling by B cells was aggregated by patient type and timepoint.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S4. Supporting data for Figure 1. Expression of genes related to BCR signaling by B cells was aggregated by patient type and timepoint.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S3: Differential gene expression analysis for IBS- and IBR-enriched clusters
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S3: Differential gene expression analysis for IBS- and IBR-enriched clusters
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S1. Supporting data for Figure 1. A. Distribution of reference cell type identities across major cell clusters (partitions). B. Expression of partition top markers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S1. Supporting data for Figure 1. A. Distribution of reference cell type identities across major cell clusters (partitions). B. Expression of partition top markers.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental table S4: Gene set enrichment analysis
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental table S4: Gene set enrichment analysis
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S2: Gene modules and top markers
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S2: Gene modules and top markers
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S1: Sequencing metrics for each sample
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S1: Sequencing metrics for each sample
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S5. Supporting data for Figure 3. A. Individual T and NK cell labels transferred via Seurat. B. T and NK cell subclusters. C. Proportion of reference cell type labels attributed to subclusters after aggregation. D. Classification of T and NK cell subclusters by differential representation analysis. E. Gene set enrichment analysis comparing the IBS-enriched CD4 TCM cluster to the IBR-enriched TCM cluster (top), and the IBS-enriched CD4 TCM cluster to the CD4 Naïve Cluster. Gene sets used were GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP and HALLMARK_TNFA_SIGNALING_VIA_NFKB, respectively. F. TCR diversity according to ibrutinib response and timepoint (Shannon’s Diversity; *: p < 0.05, Wilcoxon test).
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S5. Supporting data for Figure 3. A. Individual T and NK cell labels transferred via Seurat. B. T and NK cell subclusters. C. Proportion of reference cell type labels attributed to subclusters after aggregation. D. Classification of T and NK cell subclusters by differential representation analysis. E. Gene set enrichment analysis comparing the IBS-enriched CD4 TCM cluster to the IBR-enriched TCM cluster (top), and the IBS-enriched CD4 TCM cluster to the CD4 Naïve Cluster. Gene sets used were GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP and HALLMARK_TNFA_SIGNALING_VIA_NFKB, respectively. F. TCR diversity according to ibrutinib response and timepoint (Shannon’s Diversity; *: p < 0.05, Wilcoxon test).
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S7. Supporting data for Figure 4. A. Individual monocyte labels transferred via Seurat. B. Monocyte subclusters. C. Proportion of reference cell type labels attributed to monocyte subclusters after aggregation. D. Classification of CD14+ monocyte subclusters by differential representation analysis. E. Classification of CD16+ monocytes by differential representation analysis.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S7. Supporting data for Figure 4. A. Individual monocyte labels transferred via Seurat. B. Monocyte subclusters. C. Proportion of reference cell type labels attributed to monocyte subclusters after aggregation. D. Classification of CD14+ monocyte subclusters by differential representation analysis. E. Classification of CD16+ monocytes by differential representation analysis.